GlassScriptPhysician profile
Joseph A Henske
NPI 1366635807
$22,787.45
in general payments reported to CMS, 2019-2025
20 companies · $462 in 2025
The $462 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2021: $2,698 · 2022: $4,394 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $462.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15,204.05 | 2019-2022 | |
| Dexcom, INC. | $6,077.76 | 2019-2022 | |
| Abbvie INC. | $462.25 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $143.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $135.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $96.55 | 2019 | |
| Valeritas, INC. | $89.71 | 2019 | |
| Shire North American Group INC | $87.48 | 2019 | |
| Senseonics, Incorporated | $86.00 | 2019 | |
| Mannkind Corporation | $72.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.31 | 2019 | |
| Merck Sharp & Dohme LLC | $48.26 | 2019 | |
| Corcept Therapeutics | $36.21 | 2019 | |
| Tandem Diabetes Care, INC. | $35.96 | 2019 | |
| Insulet Corporation | $34.33 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Companion Medical, INC. | $33.28 | 2019 | |
| Amgen INC. | $33.16 | 2019 | |
| Lilly USA, LLC | $22.87 | 2019 | |
| Medtronic Minimed, INC. | $15.31 | 2019 | |
| Vivus LLC | $10.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Henske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.